ストックスクリーナーアプリを入手
5.13
5.00%
-0.27
プレマーケット:
5.13
Unicycive Therapeutics Inc (UNCY) 最新ニュース
Unicycive Therapeutics Inc (UNCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY - TradingView
Unicycive Therapeutics Inc (UNCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
UNCY|Unicycive Therapeutics Inc|Price:5.185|Chg%:-0.215 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive The - The National Law Review
TradingKey - TradingKey
Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bronstein, Gewirtz & Grossman, LLC (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unicycive Therapeutics Inc (UNCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Unicycive Therapeutics Inc (UNCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - Stocktwits
Unicycive Therapeutics Inc (UNCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeut - The National Law Review
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-07-15 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group - The Globe and Mail
UNCY: Unicycive Therapeutics Investors with Losses Should - GlobeNewswire
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation - GlobeNewswire Inc.
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc. - GlobeNewswire
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY) - Stock Titan
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
Weekly Recap: FDA acceptance, June 29 date and Brokers keep Buy ratings - TradingView
Law firm probes Unicycive Therapeutics over pos... - Pluang
Price to book forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
Price to earnings forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCYUnicycive Therapeutics Inc Short Interest - Finviz
Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position - The Globe and Mail
Bragar Eagel & Squire, P.C. is Investigating Unicycive - GlobeNewswire
Unicycive Therapeutics, Inc. Files Form 8-K for Key Event on July 2, 2026 – Company Details, NASDAQ Ticker, and Emerging Growth Status – Minichart - Minichart
Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026 - TradingView
Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update - Stock Titan
$Unicycive Therapeutics (UNCY.US)$ FDA reject on the previous reject. See below. - Moomoo
UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton - marketscreener.com
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Form 144 Unicycive Therapeutics For: 1 July By Investing.com - Investing.com Nigeria
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies - Yahoo Finance
Unicycive Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Unicycive plummets following second CRL for OLC for hyperphosphatemia - MSN
UNCY Maintained by Benchmark -- Price Target Lowered to $13.00 - GuruFocus
UNCY Maintained by Noble Capital Markets -- Price Target Lowered to $50 - GuruFocus
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for Securities Fraud by Block & ... - Caledonian Record
UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for - GlobeNewswire
Benchmark cuts Unicycive Therapeutics price target on FDA setback - Investing.com UK
Why Is Unicycive Therapeutics Stock Falling Tuesday? - Sahm
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Unicycive Therapeutics (NASDAQ:UNCY) Is In A Good Position To Deliver On Growth Plans - Moomoo
Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story (NASDAQ:UNCY) - Seeking Alpha
Benchmark cuts Unicycive Therapeutics price target on FDA setback By Investing.com - Investing.com South Africa
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):